On the mechanism of the so-called uncoupling effect of medium- and short-chain fatty acids.
Octanoate applied to rat liver mitochondria respiring with glutamate plus malate or succinate (plus rotenone) under resting-state (State 4) conditions stimulates oxygen uptake and decreases the membrane potential, both effects being sensitive to oligomycin but not to carboxyatractyloside. Octanoate also decreases the rate of pyruvate carboxylation under the same conditions, this effect being correlated with the decrease of intramitochondrial content of ATP and increase of AMP. The decrease of pyruvate carboxylation and the change of mitochondrial adenine nucleotides are both reversed by 2-oxoglutarate. Fatty acids of shorter chain length have similar effects, though at higher concentrations. Addition of octanoate in the presence of fluoride (inhibitor of pyrophosphatase) produces intramitochondrial accumulation of pyrophosphate, even under conditions when oxidation of octanoate is prevented by rotenone. In isolated hepatocytes incubated with lactate plus pyruvate, octanoate also increases oxygen uptake and produces a shift in the profile of adenine nucleotides similar to that observed in isolated mitochondria. It decreases the 'efficiency' of gluconeogenesis, as expressed by the ratio between an increase of glucose production and an increase of oxygen uptake upon addition of gluconeogenic substrates (lactate plus pyruvate), and increases the reduction state of mitochondrial NAD. These effects taken together are not compatible with uncoupling, but point to intramitochondrial hydrolysis of octanoyl-CoA and probably also shorter chain-length acyl-CoAs. This mechanism probably functions as a 'safety valve' preventing a drastic decrease of intramitochondrial free CoA under a large supply of medium- and short-chain fatty acids.
Schönfeld
P
P
Institut für Biochemie der Medizinischen Akademie Magdeburg, G.D.R.
Wojtczak
A B
AB
Geelen
M J
MJ
Kunz
W
W
Wojtczak
L
L
D000085:Acetates / Q000494:pharmacology; D000227:Adenine Nucleotides / Q000378:metabolism; D000818:Animals; D002087:Butyrates / Q000494:pharmacology; D020148:Butyric Acid; D002210:Caprylates / Q000494:pharmacology; D005227:Fatty Acids / Q000494:pharmacology*; D005232:Fatty Acids, Volatile / Q000494:pharmacology*; D005260:Female; D007656:Ketoglutaric Acids / Q000494:pharmacology; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D008930:Mitochondria, Liver / Q000187:drug effects / Q000378:metabolism*; D009243:NAD / Q000378:metabolism; D009840:Oligomycins / Q000494:pharmacology; D010101:Oxygen Consumption / Q000187:drug effects; D010710:Phosphates / Q000378:metabolism; D011773:Pyruvates / Q000378:metabolism; D019289:Pyruvic Acid; D051381:Rats; D011919:Rats, Inbred Strains; D012402:Rotenone / Q000494:pharmacology; D013386:Succinates / Q000378:metabolism; D019802:Succinic Acid
D000085:Acetates; D000227:Adenine Nucleotides; D002087:Butyrates; D002210:Caprylates; D005227:Fatty Acids; D005232:Fatty Acids, Volatile; D007656:Ketoglutaric Acids; D009840:Oligomycins; D010710:Phosphates; D011773:Pyruvates; D013386:Succinates; D012402:Rotenone; D009243:NAD; D020148:Butyric Acid; D019289:Pyruvic Acid; D019802:Succinic Acid; C031492:octanoic acid